New Application of Buprenorphine Patch on Painful Knee Joint in Knee Osteoarthritis Patients

Brief Summary

Detailed Description

Osteoarthritis (OA) is one of the most disabling diseases in developed countries. Pain is the most uncomfortable symptom, often difficult to manage because it is aggravated by weight bearing and movement of hip and knee joints. Paracetamol, traditional nonsteroidal-anti-inflammatory drugs (NSAIDs), and cyclooxygenase (COX) -2 specific inhibitors may relieve pain of joints origin. NSAIDs and COX-2 inhibitors have many potentially serious side effects, especially in elderly patients. The 2008 and 2009 guidelines now recommend weak opioids or low doses of strong opioids when paracetamol, with or without topical NSAIDs, does not relieve pain sufficiently. However, whereas several randomized controlled studies have showed analgesic effects in musculoskeletal disease, adverse effects are common, and about 50% discontinue opioid treatment because of adverse effects. Meanwhile, intra-articular (IA) opioid injection has been studied for some time. Opioid binding receptors have been identified within synovium of joint space, suggesting that analgesic effect of opioid injected into IA space may be locally mediated. When injected at the end of arthroscopic surgery, IA opioid could reduce postoperative pain through peripheral opioid receptors. It has also been reported to reduce pain through other pathways such as inflammatory reaction. We suggest the method of application of buprenorphine transdermal patch instead of intra-articular injection and the hypothesis that application of opioid transdermal patch on painful joint would transport opioid component to joint space by diffusion. This hypothesis had been named Jong's hypothesis after Jong Bum Choi, the originator. We had applied buprenorphine transdermal patch at painful knee joint in knee OA patients, and they had showed good analgesic effect and low adverse effects. The purpose of this research is to show the analgesic effects, adverse effects and compliance of buprenorphine transdermal patch applied on painful knee joint in knee OA patients and compare knee applied group with conventional chest applied group in all parameters. In medical records, we will retrospectively enroll about 200 patients with OA who were not responds to conventional therapy. Inclusion criteria were as next. 1) Age over 20, 2) diagnosis of osteoarthritis of the knee by radiographic evidence of osteoarthritis of the knee, as defined by Grades II to IV of the Kellgren and Lawrence scale, 3) Pain score over 4 in NRS from the relevant joint 4) buprenorphine transdermal patch prescribed in unilateral OA of knee. Exclusion criteria were as next. 1) total knee replacement surgery history, 2) patients treated with weak or strong opioid analgesics, 3) patients had contraindications to treatment with opioid medication, such as history of alcohol or substance abuse, 4) patients had clinically significant systemic disease or any reduced organ function, 5) patient was using antidepressants, antiepileptic drug, steroids, hypnotics (that may increase respiratory depression of buprenorphine). Patients were divided two groups. One group is the patients with chest applied buprenorphine transdermal patch, and the other group is the patients with painful knee joint applied buprenorphine transdermal patch. NRS will be checked before and next visit (at 2 weeks or 1month after prescription of buprenorphine transdermal patch). Adverse effects of buprenorphine transdermal patches will be checked and recorded. Compliance of buprenorphine transdermal patch was investigated. All parameters will be compared in chest applied group with knee applied group. The t-test will be used to compare the chest applied group and knee applied group in demographic data. The Mann-Whitney test, Chi-squared test, and Fisher's exact test will be used to compare two groups in NRS, adverse effects, compliance and dose of buprenorphine. All statistical analyses will be performed by use of R software, version 3.5.1. A p-value less than 0.05 will be considered to be statistically significant.

Primary Outcomes

Secondary Outcomes

• compliance of buprenorphine transdermal patch(up to 1 month)
• adverse effects(up to 1 month)